Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corp (NQ: PODD )

266.27 +3.34 (+1.27%)
Streaming Delayed Price Updated: 11:54 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corp

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Recap: Insulet Q2 Earnings
Insulet (NASDAQ:PODD) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Insulet missed estimated earnings by... 
Via Benzinga
Insulet Reports Second Quarter 2022 Revenue Increase of 14% Year-Over-Year (18% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System
From Insulet Corporation
Via Business Wire
The Healthcare Companies Fighting the World’s Biggest Killers
Palm Beach, FL – July 13, 2022 – FinancialNewsMedia.com News Commentary – Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the... 
Via FinancialNewsMedia
5 Analysts Have This to Say About Insulet
Insulet (NASDAQ:PODD) has observed the following analyst ratings within the last quarter: 
Via Benzinga
4 Analysts Have This to Say About Insulet
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 11, 2022
Upgrades 
Via Benzinga
Insulet to Announce Second Quarter 2022 Financial Results on August 4, 2022
From Insulet Corporation
Via Business Wire
Expert Ratings for Insulet
Within the last quarter, Insulet (NASDAQ:PODD) has observed the following analyst ratings: 
Via Benzinga
7 Stocks to Buy That Could Make You a Millionaire
These seven of the best stocks to buy in June. TXG, BRKR, ETSY, PODD, MAR, RH and SEDG can make excellent investments. 
Via InvestorPlace
Comparing Fitbits To Medical Devices? This Company Says Things Aren't Even Close
The health and wellness industry focused on the well-being of the body, mind and spirit has captured the globe's attention. According to management consulting firm, Mckinsey & Co., the global wellness... 
Via Benzinga
Omnipod® 5 Automated Insulin Delivery System Significantly Improves Glycemic Outcomes Over 12 Months of Use in Children Aged 2 through 5.9 Years
From Insulet Corporation
Via Business Wire
Insulet to Present at the William Blair & Company 42nd Annual Growth Stock Conference
From Insulet Corporation
Via Business Wire
Insulet Hosts Groundbreaking Ceremony for its New Manufacturing Facility in Malaysia
From Insulet Corporation
Via Business Wire
Dexcom Pops After Insulet Buyout Rumor Shakes Up Diabetes Stocks
The deal would have been transformative, but may have limited teamwork in the space. 
Via Investor's Business Daily
Looking Into Insulet's Return On Capital Employed
According to Benzinga Pro, during Q1, Insulet (NASDAQ:PODD) earned $27.80 million, a 4.79% increase from the preceding quarter. Insulet's sales decreased to $295.40 million, a 4.0% change since Q4. 
Via Benzinga
How The Rumored Dexcom-Insulet Marriage Could Rock The Entire Diabetes Space
One analyst called the rumored deal "transformative," but says the timing is unfavorable. 
Via Investor's Business Daily
PODD Stock Pops 7% as DexCom Considers Insulet Corporation Acquisition
Insulet (PODD) stock is heading higher on Tuesday as investors react to reports that DexCom (DXCM) is considering acquiring the company. 
Via InvestorPlace
Dexcom In Talks To Acquire Insulet, Create a Giant In Diabetes Devices: Bloomberg
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on
Good morning, trader! We're jumping into trading on Tuesday with an overview of the biggest pre-market stock movers this morning! 
Via InvestorPlace
Citigroup Maintains Buy Rating for Insulet: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Insulet (NASDAQ:PODD) and lower its price target from $350.00 to $310.00. Shares of Insulet are trading up 1.23% over the last 24 hours, at $199.34... 
Via Benzinga
10 Biggest Price Target Changes For Tuesday
Citigroup cut the price target on Insulet Corporation (NASDAQ: PODD) from $350 to $310. Insulet shares fell 1.1% to close at $196.91 on Monday. 
Via Benzinga
Recap: Insulet Q1 Earnings
Insulet (NASDAQ:PODD) reported its Q1 earnings results on Thursday, May 5, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Insulet beat estimated earnings by... 
Via Benzinga
Insulet Announces CEO Transition
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2022 Revenue Increase of 17% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet’s 2021 Sustainability Report Reveals Progress on Strategy to Deliver Growth with Purpose
From Insulet Corporation
Via Business Wire
Insulet Highlights New Data For Omnipod 5 System For Type 1, Type 2 Diabetes
Insulet Corporation (NASDAQ: PODD) unveiled study results for the new Omnipod 5 automated insulin delivery system in type 1 and type 2 diabetes patients. Paired with... 
Via Benzinga
Insulet Presents New Omnipod® 5 System Data for Type 1 and Type 2 Diabetes
From Insulet Corporation
Via Business Wire
Insulet to Announce First Quarter 2022 Financial Results on May 5, 2022
From Insulet Corporation
Via Business Wire
Insulet Posts Street-Beating Q4 Earnings, Omnipod Revenues Up ~20%
Insulet Corp's (NASDAQ: PODD) Q4 FY21 revenue increased 25% (25.7% in constant currency) to $307.7 million, exceeding the consensus of $301.06 million. The company... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.